Abstract
We conducted a phase 3 randomized controlled trial looking at the immunogenicity and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule. SBA MenC titers > or =1:8 and anti-PRP concentrations > or =0.15 microg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT.
Publication types
-
Clinical Trial, Phase III
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Bacterial / blood
-
Diphtheria-Tetanus-Pertussis Vaccine / administration & dosage
-
Diphtheria-Tetanus-Pertussis Vaccine / adverse effects
-
Diphtheria-Tetanus-Pertussis Vaccine / immunology
-
Haemophilus Infections / prevention & control
-
Haemophilus Vaccines / administration & dosage*
-
Haemophilus Vaccines / adverse effects
-
Haemophilus Vaccines / immunology
-
Haemophilus influenzae type b / immunology*
-
Humans
-
Immunization
-
Immunization Schedule
-
Infant
-
Meningococcal Infections / prevention & control
-
Meningococcal Vaccines / administration & dosage*
-
Meningococcal Vaccines / adverse effects
-
Meningococcal Vaccines / immunology
-
Neisseria meningitidis, Serogroup C / immunology*
-
Poliovirus Vaccine, Inactivated / administration & dosage
-
Poliovirus Vaccine, Inactivated / adverse effects
-
Poliovirus Vaccine, Inactivated / immunology
-
Tetanus Toxoid / administration & dosage*
-
Tetanus Toxoid / adverse effects
-
Tetanus Toxoid / immunology
-
Vaccines, Combined / administration & dosage*
-
Vaccines, Combined / adverse effects
-
Vaccines, Combined / immunology
-
Vaccines, Conjugate* / administration & dosage
-
Vaccines, Conjugate* / adverse effects
-
Vaccines, Conjugate* / immunology
Substances
-
Antibodies, Bacterial
-
Diphtheria-Tetanus-Pertussis Vaccine
-
Haemophilus Vaccines
-
Meningococcal Vaccines
-
Poliovirus Vaccine, Inactivated
-
Tetanus Toxoid
-
Vaccines, Combined
-
Vaccines, Conjugate